Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab dosing regimens with cisplatin/capecitabine in first-line HER2-positive metastatic gastric cancer
CTR20140021Phase 3Active
- Sponsor
- Roche
- Start
- Jun 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Roche. Started Jun 2014; status: active.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20140021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140021.